PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Expression of tripartite motif-containing protein 28 in primary breast carcinoma predicts metastasis and is involved in the stemness, chemoresistance, and tumor growth.

Abstract The prediction of who develops metastasis has been the most difficult aspect in the management of breast cancer patients. The lymph node metastasis has been the most useful predictor of prognosis and patient management. However, a good proportion of patients with lymph node positivity remain disease free for 5 years or more, while about a third of those who were lymph node negative develop distant metastasis within the same period. This warrants a robust biomarker(s), preferably gene expression based. In order to elucidate gene-based biomarkers for prognosis of breast cancers, gene expression profiling of primary tumors and follow-up for over 5 years has been performed. The analysis revealed a network of genes centered around the tripartite motif-containing protein 28 as an important indicator of disease progression. Short hairpin RNA-mediated knockdown of tripartite motif-containing protein 28 in breast cancer cells revealed a decreased expression of epithelial-to-mesenchymal transition markers and increased expression of epithelial markers, decreased migration and invasion, and increased chemosensitivity to doxorubicin, 5-fluorouracil, and methotrexate. Furthermore, knockdown of tripartite motif-containing protein 28 resulted in the decrease of stemness as revealed by sphere formation assay as well as decreased expression of CD44 and Bmi1. Moreover, tripartite motif-containing protein 28 knockdown significantly reduced the tumor size and lung metastasis in orthotopic tumor xenograft assay in immunocompromised mice. The tumor size was further reduced when these mice were treated with doxorubicin. These data provide evidence for tripartite motif-containing protein 28 as a biomarker and a potential therapeutic target for breast cancer.
PMID
Related Publications

ERα inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancer.

RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.

Activation of microRNA-494-targeting Bmi1 and ADAM10 by silibinin ablates cancer stemness and predicts favourable prognostic value in head and neck squamous cell carcinomas.

Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.

Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.

Authors

Mayor MeshTerms
Keywords

Tripartite motif-containing protein 28

chemoresistance

epithelial-to-mesenchymal transition

microarray

stemness

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28381187
OWN - NLM
STAT- MEDLINE
DA  - 20170406
DCOM- 20170418
LR  - 20170418
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 4
DP  - 2017 Apr
TI  - Expression of tripartite motif-containing protein 28 in primary breast carcinoma 
      predicts metastasis and is involved in the stemness, chemoresistance, and tumor
      growth.
PG  - 1010428317695919
LID - 10.1177/1010428317695919 [doi]
AB  - The prediction of who develops metastasis has been the most difficult aspect in
      the management of breast cancer patients. The lymph node metastasis has been the 
      most useful predictor of prognosis and patient management. However, a good
      proportion of patients with lymph node positivity remain disease free for 5 years
      or more, while about a third of those who were lymph node negative develop
      distant metastasis within the same period. This warrants a robust biomarker(s),
      preferably gene expression based. In order to elucidate gene-based biomarkers for
      prognosis of breast cancers, gene expression profiling of primary tumors and
      follow-up for over 5 years has been performed. The analysis revealed a network of
      genes centered around the tripartite motif-containing protein 28 as an important 
      indicator of disease progression. Short hairpin RNA-mediated knockdown of
      tripartite motif-containing protein 28 in breast cancer cells revealed a
      decreased expression of epithelial-to-mesenchymal transition markers and
      increased expression of epithelial markers, decreased migration and invasion, and
      increased chemosensitivity to doxorubicin, 5-fluorouracil, and methotrexate.
      Furthermore, knockdown of tripartite motif-containing protein 28 resulted in the 
      decrease of stemness as revealed by sphere formation assay as well as decreased
      expression of CD44 and Bmi1. Moreover, tripartite motif-containing protein 28
      knockdown significantly reduced the tumor size and lung metastasis in orthotopic 
      tumor xenograft assay in immunocompromised mice. The tumor size was further
      reduced when these mice were treated with doxorubicin. These data provide
      evidence for tripartite motif-containing protein 28 as a biomarker and a
      potential therapeutic target for breast cancer.
FAU - Damineni, Surekha
AU  - Damineni S
AD  - 1 Indian Institute of Science, Bangalore, India.
FAU - Balaji, Sai A
AU  - Balaji SA
AD  - 2 Strand Life Sciences, Bangalore, India.
FAU - Shettar, Abhijith
AU  - Shettar A
AD  - 1 Indian Institute of Science, Bangalore, India.
FAU - Nayanala, Swetha
AU  - Nayanala S
AD  - 2 Strand Life Sciences, Bangalore, India.
FAU - Kumar, Neeraj
AU  - Kumar N
AD  - 1 Indian Institute of Science, Bangalore, India.
FAU - Kruthika, Banavathy S
AU  - Kruthika BS
AD  - 1 Indian Institute of Science, Bangalore, India.
FAU - Subramanian, Kalyanasundaram
AU  - Subramanian K
AD  - 2 Strand Life Sciences, Bangalore, India.
FAU - Vijayakumar, M
AU  - Vijayakumar M
AD  - 3 Kidwai Institute of Oncology, Bangalore, India.
FAU - Mukherjee, Geetashree
AU  - Mukherjee G
AD  - 3 Kidwai Institute of Oncology, Bangalore, India.
FAU - Gupta, Vaijayanti
AU  - Gupta V
AD  - 2 Strand Life Sciences, Bangalore, India.
FAU - Kondaiah, Paturu
AU  - Kondaiah P
AD  - 1 Indian Institute of Science, Bangalore, India.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Antigens, CD44)
RN  - 0 (CD44 protein, human)
RN  - 0 (Repressor Proteins)
RN  - 0 (TRIM28 protein, human)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - Antigens, CD44/analysis
MH  - Breast Neoplasms/drug therapy/*pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Doxorubicin/pharmacology
MH  - Drug Resistance, Neoplasm
MH  - Epithelial-Mesenchymal Transition
MH  - Female
MH  - Humans
MH  - Mice
MH  - Neoplasm Metastasis
MH  - Repressor Proteins/analysis/*physiology
OTO - NOTNLM
OT  - Tripartite motif-containing protein 28
OT  - chemoresistance
OT  - epithelial-to-mesenchymal transition
OT  - microarray
OT  - stemness
EDAT- 2017/04/07 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/07 06:00
AID - 10.1177/1010428317695919 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Apr;39(4):1010428317695919. doi: 10.1177/1010428317695919.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>